Frequency and Early Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Longitudinal Population‐Based Study
Open Access
- 1 February 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 97 (6) , 1122-1133
Abstract
Objective: The objective is to evaluate cognitive and behavioral progression and identify early predictors of these changes in a cohort of amyotrophic lateral sclerosis (ALS) patients.Methods: A total of 161 ALS patients were tested at diagnosis (T0), and 107 were re‐tested after 1 year (T1) using cognitive/behavioral tests. All patients underwent whole‐genome sequencing, and 46 patients (ALS‐normal cognition [CN]) underwent [18F]Fluorodeoxyglucose positron emission tomography.Results: Of the 161 patients, 107 were re‐rested at T1; non‐retested patients included 10 with frontotemporal dementia and 44 who were either non‐testable or deceased. At T0, 67 patients (62.6%) were classified as ALS‐CN, whereas 40 (38.4%) showed some degree of cognitive/behavioral impairment. Eighteen ALS‐CN patients (26.9%) experienced cognitive decline at T1. Phenoconverters had lower baseline scores in letter fluency (Letter Fluency Test [FAS]) (p < 0.001), Edinburgh Cognitive and Behavioral ALS Screen (ECAS) verbal fluency score (p = 0.017). Both tests were independently predictive of phenoconversion in binary logistic regression models, with optimal cut‐off scores of 28.75 and 14.2, with good sensitivity and specificity. Other predictors included older age, lower education, and ALS‐related genetic variants. Phenoconverters were hypometabolic in the left temporal lobe. Thirteen (32.5%) of the 40 patients with cognitive impairment at T0 worsened by T1, with FAS (p = 0.02) and the ECAS verbal fluency score (p = 0.023) predicting further decline.Interpretation: Approximately 30% of ALS patients experienced cognitive/behavioral decline within the first year after diagnosis. FAS and ECAS verbal fluency were predictive of cognitive phenoconversion. Our findings highlight the importance of early detection of at‐risk individuals and the need for longitudinal cognitive assessments to monitor disease progression. ANN NEUROL 2025;97:1122–1133Keywords
Funding Information
- HORIZON EUROPE Health (101017598)
- Ministero della Salute (RF‐2016‐02362405)
- FP7 Health (259867)
This publication has 50 references indexed in Scilit:
- Repeated cognitive assessments show stable function over time in patients with ALSJournal of Neurology, 2024
- Cognitive function in amyotrophic lateral sclerosis: a cross-sectional and prospective pragmatic clinical study with review of the literatureNeurological Sciences, 2023
- EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Anatomy of phonemic and semantic fluency: A lesion and disconnectome study in 1231 stroke patientsCortex, 2021
- A proposal for new diagnostic criteria for ALSClinical Neurophysiology, 2020
- Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosisCortex, 2018
- Secular Trends of Amyotrophic Lateral SclerosisJAMA Neurology, 2017
- Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trialsAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015
- A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of DementiaNeuroinformatics, 2014
- Value of18Fluorodeoxyglucose–Positron-Emission Tomography in Amyotrophic Lateral SclerosisJAMA Neurology, 2014